- Home
- Publications
- Publication Search
- Publication Details
Title
Treatments for NAFLD: State of Art
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 5, Pages 2350
Publisher
MDPI AG
Online
2021-02-27
DOI
10.3390/ijms22052350
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial
- (2021) Anat Yaskolka Meir et al. GUT
- Management of non-alcoholic fatty liver disease
- (2021) Maria Letizia Petroni et al. BMJ-British Medical Journal
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk
- (2021) Dong D. Wang et al. NATURE MEDICINE
- Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
- (2020) A. Mantovani et al. DIABETES & METABOLISM
- Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease
- (2020) Eleonora Scorletti et al. GASTROENTEROLOGY
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Complications, morbidity and mortality of nonalcoholic fatty liver disease
- (2020) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View
- (2020) Rodrigo Valenzuela et al. Nutrients
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus
- (2020) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Effects of Metformin Exposure on Survival in a Large National Cohort of Patients with Diabetes and Cirrhosis
- (2020) David E. Kaplan et al. Clinical Gastroenterology and Hepatology
- Exercise and metabolic health: beyond skeletal muscle
- (2020) John P. Thyfault et al. DIABETOLOGIA
- Metabolic liver disease in diabetes – From mechanisms to clinical trials
- (2020) Bedair Dewidar et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
- (2020) Rohit Loomba et al. Lancet Gastroenterology & Hepatology
- A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
- (2020) Stephen A Harrison et al. Lancet Gastroenterology & Hepatology
- Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD
- (2020) Xiaofan Jiang et al. Frontiers in Medicine
- Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease
- (2020) Jung Il Lee et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
- (2020) Stephen A. Harrison et al. Contemporary Clinical Trials
- Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
- (2020) Francisca dos Santos Coelho et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- NAFLD, MAFLD and DAFLD
- (2020) Alessandro Mantovani et al. DIGESTIVE AND LIVER DISEASE
- Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
- (2020) Sven Francque et al. Nature Reviews Gastroenterology & Hepatology
- Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis
- (2020) Cheng-Han Lee et al. Nutrients
- Relationship between dietary patterns and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
- (2020) Shirin Hassani Zadeh et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Nutritional Approaches for the Management of Nonalcoholic Fatty Liver Disease: An Evidence-Based Review
- (2020) Marcela Parra-Vargas et al. Nutrients
- Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
- (2020) Alessandro Mantovani et al. Metabolites
- Cigarette Smoking Increased Risk of Overall Mortality in Patients With Non-alcoholic Fatty Liver Disease: A Nationwide Population-Based Cohort Study
- (2020) Phunchai Charatcharoenwitthaya et al. Frontiers in Medicine
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma
- (2019) Lena Schulte et al. LIVER INTERNATIONAL
- Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease
- (2019) Ki Tae Suk et al. Expert Review of Gastroenterology & Hepatology
- Pioglitazone Therapy in Patients With Stroke and Prediabetes
- (2019) J. David Spence et al. JAMA Neurology
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease
- (2019) Tracey G. Simon et al. Clinical Gastroenterology and Hepatology
- Vitamin E Ameliorates Lipid Metabolism in Mice with Nonalcoholic Fatty Liver Disease via Nrf2/CES1 Signaling Pathway
- (2019) Wenxi He et al. DIGESTIVE DISEASES AND SCIENCES
- Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
- (2019) Mohsen Malehmir et al. NATURE MEDICINE
- Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
- (2019) Eduardo Vilar-Gomez et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
- (2019) Srilaxmi Kalavalapalli et al. JOURNAL OF ENDOCRINOLOGY
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
- (2019) Niki Katsiki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease
- (2019) Nienke Koopman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
- (2019) Marc Foretz et al. Nature Reviews Endocrinology
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes
- (2019) Jian Zhou et al. Annals of Hepatology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
- (2018) Alessandro Mantovani et al. DIABETES CARE
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Ad libitum Mediterranean and Low Fat Diets both Significantly Reduce Hepatic Steatosis: a Randomized Controlled Trial
- (2018) Catherine Properzi et al. HEPATOLOGY
- Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
- (2018) Oliver Krenkel et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
- (2018) Amedeo Lonardo et al. JOURNAL OF HEPATOLOGY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement
- (2018) Frédéric Brioude et al. Nature Reviews Endocrinology
- Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts
- (2018) Ramón Estruch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
- (2018) Ivana Mikolasevic et al. WORLD JOURNAL OF GASTROENTEROLOGY
- A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
- (2018) Marina Kawaguchi-Suzuki et al. Frontiers in Pharmacology
- Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population
- (2018) Matthieu Wargny et al. ATHEROSCLEROSIS
- Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease
- (2018) Huikuan Chu et al. GUT
- Ad libitum Mediterranean or low fat diets as treatments for non-alcoholic fatty liver disease?
- (2018) Giovanni Targher et al. HEPATOLOGY
- Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
- (2018) Vincent Wai-Sun Wong et al. JOURNAL OF HEPATOLOGY
- Statins: Old drugs as new therapy for liver diseases?
- (2018) Elisa Pose et al. JOURNAL OF HEPATOLOGY
- Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-Analysis
- (2018) Yung Lee et al. Clinical Gastroenterology and Hepatology
- The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors
- (2018) Eleni Theocharidou et al. CURRENT PHARMACEUTICAL DESIGN
- 5. Lifestyle Management: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Not all NAFLD patients are the same: We need to find a personalized therapeutic approach
- (2018) Alessandro Mantovani DIGESTIVE AND LIVER DISEASE
- Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease
- (2018) Emanuel Raschi et al. EXPERT OPINION ON PHARMACOTHERAPY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis
- (2017) Yukiomi Nakade et al. HEPATOLOGY RESEARCH
- Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
- (2017) Ryuki Hashida et al. JOURNAL OF HEPATOLOGY
- Treatment of NAFLD with diet, physical activity and exercise
- (2017) Manuel Romero-Gómez et al. JOURNAL OF HEPATOLOGY
- The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms
- (2017) Shira Zelber-Sagi et al. LIVER INTERNATIONAL
- The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
- (2017) Vasilios G. Athyros et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
- (2017) Stuart McPherson et al. PLoS One
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- High-Intensity Aerobic Exercise Improves Both Hepatic Fat Content and Stiffness in Sedentary Obese Men with Nonalcoholic Fatty Liver Disease
- (2017) Sechang Oh et al. Scientific Reports
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Recommended Dietary Pattern to Achieve Adherence to the American Heart Association/American College of Cardiology (AHA/ACC) Guidelines: A Scientific Statement From the American Heart Association
- (2016) Linda Van Horn et al. CIRCULATION
- Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: A 1-year follow-up study
- (2016) Hui-Jie Zhang et al. DIABETES OBESITY & METABOLISM
- Non-alcoholic steatohepatitis and liver transplantation
- (2016) Stefano Gitto et al. DIGESTIVE AND LIVER DISEASE
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- (2016) Yaron Rotman et al. GUT
- Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice
- (2016) Giulio Marchesini et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
- (2016) Stefano Ballestri et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Bariatric surgery for obesity and metabolic disorders: state of the art
- (2016) Ninh T. Nguyen et al. Nature Reviews Gastroenterology & Hepatology
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review
- (2016) Pegah Golabi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
- (2016) Jessica Glen et al. BMJ-British Medical Journal
- Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
- (2016) Jessica Glen et al. BMJ-British Medical Journal
- Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis
- (2015) Siddharth Singh et al. HEPATOLOGY
- Statin use and non-alcoholic steatohepatitis in at risk individuals
- (2015) Paola Dongiovanni et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Nonalcoholic fatty liver disease
- (2015) Elizabeth M. Brunt et al. Nature Reviews Disease Primers
- Metformin: From Mechanisms of Action to Therapies
- (2014) Marc Foretz et al. Cell Metabolism
- PNPLA3gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease
- (2014) Jiayun Shen et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
- (2014) Fernando J. Barreyro et al. LIVER INTERNATIONAL
- Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis
- (2013) Siddharth Singh et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis
- (2013) Xiaofei Wang et al. Clinical Gastroenterology and Hepatology
- Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial)
- (2013) Elisabetta Bacchi et al. HEPATOLOGY
- Dietary fructose in nonalcoholic fatty liver disease
- (2013) Miriam B. Vos et al. HEPATOLOGY
- The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease
- (2013) Marno C. Ryan et al. JOURNAL OF HEPATOLOGY
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
- (2013) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Liver Fat Is Reduced by an Isoenergetic MUFA Diet in a Controlled Randomized Study in Type 2 Diabetic Patients
- (2012) L. Bozzetto et al. DIABETES CARE
- Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
- (2011) Michael R. Charlton et al. GASTROENTEROLOGY
- Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial
- (2011) Dawn M. Torres et al. HEPATOLOGY
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents
- (2011) Joel E. Lavine JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2011) Helen M. Parker et al. JOURNAL OF HEPATOLOGY
- Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
- (2010) Vasilios G Athyros et al. LANCET
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- (2010) Giovanni Targher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats
- (2009) Montserrat Moreno et al. HEPATOLOGY
- Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis
- (2009) Eugen Florin Georgescu et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
- (2008) Vlad Ratziu et al. GASTROENTEROLOGY
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
- The Endoplasmic Reticulum Enzyme DGAT2 Is Found in Mitochondria-associated Membranes and Has a Mitochondrial Targeting Signal That Promotes Its Association with Mitochondria
- (2008) Scot J. Stone et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet
- (2008) B. Kong et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now